坏死性凋亡在肿瘤放化疗中的研究进展与思考

Progress in research on necroptosis as a target for cancer radiotherapy and chemotherapy

  • 摘要: 肿瘤具有对程序性细胞死亡的抵抗作用,这是肿瘤细胞会产生放化疗耐受的原因之一。细胞程序性死亡不仅包括依赖含半胱氨酸的天冬氨酸蛋白水解酶(caspase)的细胞凋亡,也包括一种最近研究热门的非依赖caspase的死亡形式——坏死性凋亡。目前研究发现坏死性凋亡是由受体相互作用蛋白1(RIP1)、受体相互作用蛋白3(RIP3)以及混合谱系激酶结构域蛋白(MLKL)进行调控。笔者简要地总结了目前国内外坏死性凋亡相关的研究进展,为坏死性凋亡作为一种肿瘤放化疗新靶点的深入研究提供新思路。

     

    Abstract: A characteristic of cancer is resistance to programmed cell death, which sustains cell survival through oncogenic transformation and therapeutic resistance. Recent studies have shown that programmed cell death is not limited to caspase-dependent apoptosis. Necroptosis, a caspase-independent form of cell death, is regulated by receptor interacting protein 1, receptor interacting protein 3, and mixed lineage kinase domain-like proteins. This review summarized current research studies on necroptosis to provide perspectives for the development of novel tumor radiotherapy and chemotherapy strategies that target this process.

     

/

返回文章
返回